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Abstract
Objective—To characterize actions performed by pharmacists and support staff during provision 
of medication therapy management (MTM) and compare actions performed by practice 
characteristics.
Methods—A purposeful sample of seven MTM practices (n= 2 call centers and n=5 community 
practices) was identified and visited by investigators. Pharmacists and support staff were observed 
during their routine provision of MTM. Investigators characterized “major” (e.g., preparation for a 
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comprehensive medication review) and “minor” actions (i.e., specific steps in overarching major 
action) using a time-and-motion approach.
Results—A total of 32 major and 469 minor actions were observed. Practices were characterized 
as Later Maturity Level or Early Maturity Level based on their self-reported MTM appointment 
volume, self-assessment of the extent of integration of chronic care model principles, and payer 
mix. Later Maturity Level practices were more likely to deliver follow-up medication therapy 
reviews and comprehensive medication reviews (CMRs) as opposed to targeted medication 
reviews (TMRs), and receive physicians referrals for MTM. Later Maturity Level practices were 
also more likely to utilize paid interns than pharmacy rotation students. CMR activities observed at 
Later Maturity Level practices lasted a median of 30.8 minutes vs. 20.3 minutes for CMR 
activities at Early Maturity Level practices. Similarly, TMR activities observed at Later Maturity 
Level practices were also longer; a median 31.0 minutes vs. 12.3 minutes. At Later Maturity Level 
practices, pharmacists spent a greater proportion of time providing patient education while support 
staff spent a greater proportion of time on tasks such as capturing demographics and introducing/
explaining MTM.
Conclusion—MTM activities were longer at Later Maturity Level practices and these practices 
were more likely to utilize paid pharmacy interns and receive physician referrals for MTM. This 
work provides a foundation for future research.
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Introduction
Medications are used widely in the United States and use is growing. Among individuals 
ages 65 and older, 90% have a prescription drug expense1 and the costs of preventable 
adverse drug events in the ambulatory setting are estimated at $887 million annually.2 The 
Centers for Medicare and Medicaid Services (CMS) implemented Medicare Part D 
medication therapy management (MTM) to promote medication adherence and reduce 
adverse drug events among chronically ill beneficiaries using multiple medications.3 At 
minimum, eligible beneficiaries must be offered a comprehensive medication review (CMR) 
annually and targeted medication reviews (TMRs) quarterly. CMRs must be “person-to-
person” and conducted by a pharmacist or other provider and documented using a 
standardized CMS format.4
While some MTM studies have demonstrated cost savings and improved quality of life, 
outcomes and measures for evaluating MTM have varied considerably.5–11 This variation in 
outcomes might be due to MTM implementation challenges pertaining to staffing and time 
constraints, insufficient compensation models, and limited patient engagement.12–14 Some 
MTM models appear to be more effective and/or efficient than others and support staff have 
been encouraged to take on more active roles in MTM. However, insufficient information 
currently exists on how this has been operationalized across various practice settings and 
how time is actually spent during MTM.15–16 Time-and-motion methods have been widely 
used in health services research17–20. Applying time-and-motion methods to study MTM 
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can provide insight into how pharmacists and support staff are utilized and may identify 
potential inefficiencies and areas for future research.
Objective
To characterize actions performed by pharmacists and support staff during the provision of 
MTM and compare actions performed by practice characteristics.
Methods
Conceptual Framework
As noted above, CMS targeting criteria for MTM focuses on beneficiaries with multiple 
chronic conditions4; over 80% of Part D plans target those with at least three chronic 
conditions.21 Given this focus, the Chronic Care Model (CCM) provides a useful framework 
for examining different approaches by which MTM has been implemented; others have also 
recently suggested the integration of MTM and CCM concepts to guide research.22 The 
CCM elements include: (1) organization of the health care system, (2) delivery of services, 
(3) decision support, (4) clinical information systems, (5) patient self-management support, 
and (6) community linkages.23–24 Previous research has demonstrated that interventions 
incorporating at least one CCM element result in improvements in clinical outcomes for 
common chronic diseases.25
Enrollment
To identify a heterogeneous cross-section of MTM practices varying in type (call center vs. 
community pharmacy), ownership (independent vs. chain), payer mix (solely Medicare Part 
D MTM vs. a more diverse payer mix) and experience providing MTM, a purposeful 
sampling approach26 was applied. Study sites were recruited with assistance of the 
Medication Safety Research Network of Indiana (Rx-SafeNet)27 and leadership from the 
Minnesota Pharmacists Practice-based Research Network (MPBRN),28 as well as through 
the investigators’ professional networks. After confirmation of willingness to participate, 
practice contacts helped to identify stakeholders (pharmacists, support staff, prescribers, and 
patients) to approach for participation. Those eligible were at least 21 years old, proficient in 
English, able to consent, and either an employee participating in MTM delivery, a patient 
receiving MTM who reported having at least one chronic medical condition, or a prescriber 
interfacing with the practice through the delivery of MTM. Pharmacists and support staff at 
the participating practices, and prescribers, were informed about the study via telephone or 
email, after which the investigators discussed the study in more detail by telephone. The 
recruitment of patients took place by telephone prior to their medication therapy review or in 
the waiting area at the participating practices. Study procedures were approved by the 
Purdue University Institutional Review Board (IRB).
Data Collection
Between Fall 2013 and Spring 2015, 2 to 3 investigators (M.E.S., H.A.J., S.A.G.) visited 
each practice for 2 to 3 days to observe MTM activities and collect data using four 
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techniques, including: (1) administration of a survey tool, (2) observations and contextual 
inquiry, (3) semi-structured interviews, and (4) audio-recorded investigator debriefs.
The survey tool consisted of a modified Assessment of Chronic Illness Care (ACIC) 
instrument (v. 3.5; Appendix A, available on JAPhA.org as supplemental content),29 which 
characterizes elements of the CCM. The ACIC was administered to participating 
pharmacists and support staff to assess their perception of the extent to which CCM 
elements were incorporated by their practice into MTM delivery. Possible scores range from 
0–11 for both the overall score and the individual subscales, with higher scores indicating 
more comprehensive chronic care delivery.29 Wording modifications were made with 
permission to improve relevance to the delivery of MTM; emphasis was placed to ensure 
each question’s intent was preserved. Data for patient MTM appointment volume and 
percent of MTM appointments provided under Medicare Part D were collected as self-
reports from pharmacists and support staff following semi-structured interviews.
During observations, investigators timed a purposeful sample of the MTM activities 
observed at each practice, attempting to capture both initial and follow-up MTM encounters 
as well as activities occurring before (e.g., preparatory work), during, and after (e.g., 
documentation) the medication therapy review. Time observations were recorded as 
unstructured notes and dictated by investigators during daily debriefs for subsequent 
professional transcription and coding. These notes included: the MTM action being 
performed, the type of participant performing each action, and the time spent in minutes and 
seconds on each action.
Finally, qualitative data were collected through individual semi-structured interviews, 
investigator debriefs of observations, and contextual inquiry with practice stakeholders to 
identify themes pertaining to the CCM elements. Qualitative data procedures and findings 
are described elsewhere.30
Data Analysis
After investigators’ notes of timed observations were transcribed, we created a coding 
scheme to characterize MTM-related activities using the time-and-motion study tool 
published by the Agency for Healthcare Research and Quality (AHRQ) and the 
pharmaceutical care process as guiding frameworks.31–32 This coding scheme included both 
“Major” and “Minor” actions. Major actions were defined as the overarching MTM activity 
observed. These were: (1) preparatory work for a medication therapy review; (2) conduct of 
a medication therapy review; (3) wrap-up work, following a medication therapy review; and 
(4) contact with a patient regarding a medication therapy review. Major action codes 
included whether the MTM activity was: (1) for an initial or follow-up medication therapy 
review; (2) for a CMR or TMR; and (3) how the patient was identified for the medication 
therapy review (e.g., payer assigned patient vs. physician referral).
“Minor” actions were defined as each specific step in the MTM activity (major action) 
observed. Minor action codes included: (1) timing of action (before, during, or after the 
medication therapy review); (2) time spent; (3) person completing (e.g., pharmacist); (4) 
location (e.g., telephone); (5) the MTM Core Element being completed33 (e.g., medication 
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therapy review, personal medication record); and (6) relation of the action to the CCM 
elements (e.g., clinical decision support). Finally, if applicable, codes were assigned to 
categorize the specific component of the medication therapy review observed (e.g., review of 
allergies).
Descriptive statistics were computed using SPSS v. 23.0 to summarize MTM actions 
observed across (1) stage of practice development (i.e., maturity levels, described below), 
and (2) role of person performing observed task (i.e., pharmacist vs. support staff). An 
overall practice mean was computed from data across all participating pharmacists and 
support staff at a given practice to obtain a practice-level mean ACIC score. The mean per 
pharmacist per week number of MTM appointments and percent Part D were calculated for 
each practice using pharmacist self-report data.
Results
Summary of Practice Characteristics
Seven MTM practices participated, representing both call center (n=2) and community 
pharmacy (n=5) models for MTM delivery. Community pharmacy practices included 
independent, chain, and health-system outpatient pharmacy teams. Two maturity levels of 
MTM practice were evident based on the practices’ self-reported MTM appointment 
volume, self-assessment of the extent of integration of chronic care model (CCM) principles 
(i.e., ACIC scores), and payer mix. These levels align with those described in the Capability 
Maturity Model.34 Although originally developed to describe the maturity of information 
technology within organizations, the levels described by the Capability Maturity Model 
could have wide applications.35 In the current study, participating MTM practices appeared 
to fall along the continuum of maturity presented by Paulk, et al.34 with a natural break point 
grouping practices at either Level 1 (Initial) or Level 2 (Repeatable) vs. practices at Level 3 
(Defined), Level 4 (Managed) or Level 5 (Optimizing). We will refer to the former group as 
“Early Maturity Level” MTM practices and the latter as “Later Maturity Level” MTM 
practices. In general, Later Maturity Level practices were those with larger MTM patient 
volumes, ACIC scores indicating more comprehensive chronic care, and diversified MTM 
payer mixes (Table 1.)
Summary of Major and Minor Actions Observed
A total of 32 major and 469 minor actions were recorded (Table 1). Across all practices, no 
point of care testing or discussion of social history as part of a medication therapy review 
was observed.
Later Maturity Level versus Early Maturity Level Practices
Later Maturity Level practices were more likely to deliver follow-up medication therapy 
reviews and CMRs as opposed to TMRs. Both CMR and TMR activities observed were 
longer at Later Maturity Level Practices compared to Early Maturity Level Practices.
We observed physicians referrals for MTM at Later Maturity Level practices only. Later 
Maturity Level practices were also more likely to utilize paid interns than pharmacy rotation 
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students. Similarly, technicians were observed in MTM delivery only at Later Maturity 
Level practices. (Table 2.)
Across all practices, MTM tasks initiated by payers, physicians, and pharmacists in Later 
Maturity Level practices lasted a median of 31.0 (range: 15.2–61.8), 16.9 (range: 2.1–40.0), 
and 42.1 (range: 37.0–47.2) minutes, respectively. MTM tasks in Early Maturity Level 
practices initiated by payers and pharmacists lasted a median of 12.4 (range: 7.7–69.0) and 
16.8 (16.1–27.3) minutes.
Pharmacists versus Support Staff
Across all practices, 13.5% of 238 actions completed by pharmacists were interventions and 
referrals, compared with 1.9% of 190 actions made by support staff. In contrast, 17.1% of 
support staff actions were related to documentation/follow-up, compared to 7.1% for 
pharmacists. As a proportion of activities observed (Table 2, support staff at Later Maturity 
Level practices also conducted more demographics capturing/reviewing patient profiles/
reviewing and responding to clinical alerts than did pharmacists (21.7% vs. 4.9%) whereas it 
was similar for support staff and pharmacists at Early Stage Maturity practices (18.2% for 
support staff and 20.3% for pharmacists.) Moreover, support staff introduced/explained 
MTM more than pharmacists (9.8% vs. 1.6%) at Later Maturity Level practices but not at 
Early Maturity Level practices (5.0% vs. 4.7%.) At Early Mature Level practices, 
pharmacists and support staff devoted about the same proportion of time to providing patient 
education (20.3% vs. 17.4%) but pharmacists at Later Maturity Level practices devoted a 
much larger proportion of their time compared to support staff (24.6% vs. 10.9%.)
Discussion
In this descriptive study, we were able to group MTM practices along a maturity continuum 
based on MTM appointment volume, ACIC scores, and payer mix. While originally 
designed to describe the maturity of information technology within organizations, applying 
principles from the Capability Maturity Model to the study of MTM delivery merits further 
consideration particularly given the more recent development of service-oriented maturity 
models.36 We found that MTM tasks at Later Maturity Level practices were completed by 
more types of support staff, including paid staff, than MTM tasks completed at Early 
Maturity Level practices. Given their higher service volumes, Later Maturity Level practices 
likely have the opportunity to develop advanced workflow and scheduling logistics that 
allow specialized positions to perform specific tasks. In addition, such routinization could 
improve efficiency and reduce MTM delivery costs, thereby enhancing service 
sustainability.34
Engaging support staff, such as pharmacy technicians, in MTM aligns with contemporary 
practice recommendations. Prior literature suggests pharmacy technicians can contribute to 
MTM by contacting and scheduling patients and assisting with documentation and 
billing.37–39 In this study, we discovered that support staff at Later Maturity Level practices 
allocated a larger proportion of their time on tasks such as capturing demographics and 
introducing/explaining MTM, which may have shifted pharmacists time at these practices to 
provide more interventions and education. However, additional support staff training might 
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be required, because only 23% of the Pharmacy Technician Certification Examination 
addresses pharmacotherapy principles.40 Additionally, Pattin et al. found that training 
pharmacy technicians about their role in MTM resulted in more technicians believing that 
they could help with MTM.41
The time dedicated to MTM activities was similar to time data reported by other 
investigators.15–16,42 Both CMRs and TMRs were longer at Later Maturity Level practices 
than at Early Maturity Level practices which may indicate a more robust approach being 
taken to medication therapy reviews. These findings warrant additional research.
The reason for differences observed in time spent on MTM tasks based on referral source are 
unclear and warrant further study as the MTM consensus definition endorsed in 2004 by 11 
national pharmacy organizations states that MTM payers should include opportunities for 
pharmacists to identify patients who should receive MTM.43 However, pharmacist-initiated 
activities were observed much less commonly than those initiated by payers, and we did not 
observe every type of referral source at each practice.
Limitations
Investigator training and pilot testing focused on other components of the study visits (e.g., 
qualitative interviewing) rather than on how time notes should be recorded. Therefore, time 
was not captured for every observed task, and there were inconsistencies in noting time 
stamps at the same granularity or precision. Moreover, our coding scheme was developed 
after observations were recorded, creating inherent limitations. For example, distinguishing 
MTR from “Intervention/Referral” was difficult, because pharmacists routinely make 
interventions throughout the conduct of the MTR. This was managed through ongoing 
refinements to our coding scheme. Future studies of time spent in MTM are warranted and 
should consider a priori creation of the coding scheme, potentially based on our findings, 
with further training of observers. Given the nature of the study, we did not observe the same 
number and type of actions at every practice. We do not know the number of unique patients 
or unique MTM encounters, because not all CMRs and TMRs were observed from start to 
finish. In some instances, one investigator observed MTR preparatory work while another 
investigator observed wrap up/documentation. We do not know the percent of MTM 
appointments that were CMRs vs. TMRs as the item asked only for an approximate number 
of MTM appointments conducted per week. One practice did not provide MTM through 
Medicare Part D but this was not known until our visit. Finally, while we were successful in 
recruiting a heterogeneous national sample of MTM practices, our findings may have 
differed had we observed MTM elsewhere.
Conclusions
Patterns of MTM activities vary by stage of practice maturity and person performing the 
task, with Later Maturity Level practices more likely than Early Maturity Level practices to 
utilize paid pharmacy interns and receive physician referrals for MTM. TMR and CMR 
activities were also longer at Later Maturity Level practices and follow-up MTM activities 
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were only observed at Later Maturity Level practices. This work provides a strong 
foundation for future time-and-motion and comparative effectiveness MTM research.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Practice Characteristics by Maturity Level
Overall Practice Level of Maturity
n=7 “Early Maturity Level” (n=3)
“Later Maturity Level” 
(n=4)
Type of practice, n (%)
 Call center 2 (28.6%) 1 (33.3%) 1 (25%)
 Community 5 (71.4%) 2(66.7%) 3 (75%)
Number of staff observed per practice, median (range) 4.0 (1.0–7.0) 2.3 (1.0–4.0) 6.0 (5.0–7.0)
 Pharmacists 2.0 (1.0–9.0) 1.7 (1.0–2.0) 5.0 (2.0–9.0)
 Support staff
MTM appointments conducted/involved in per week 
per practice, median (range)
2.5 (0–300) 2.4 (0–10.0) 10 (0–300)
 Pharmacist 2.4 (0–100) 1.2 (0–10.0) 7.5 (0–100)
 Support Staff 4.0 (3–300) 4.0 (3.0–5.0) 19 (0–300)
Percent of appointments Medicare Part D per practice 69.4 (0–100) 66.7 (0–100) 62.0 (0–100)
Overall ACIC score per practice, average (SD) 7.7 (2.0) 6.4 (2.3) 8.2 (1.7)
 Pharmacist 7.2 (1.8) 6.3 (1.8) 7.6 (1.7)
 Support staff 7.6 (2.1) 7.0(2.6) 8.4 (1.6)
MTM: Medication Therapy Management
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